News

Tenax expands development of PH treatment TNX-103

Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The company last year received $100 million in funding to help it complete an ongoing Phase 3 LEVEL trial…

Targeting AURKB enzyme a promising approach in PAH rats

Inhibiting an enzyme known as Aurora kinase B (AURKB) significantly improves multiple measures of blood flow in rat models of pulmonary arterial hypertension (PAH), a study suggests. AURKB blockade worked by suppressing the excessive growth of blood vessel muscle cells, which contributes to the narrowing of pulmonary arteries that…

Pooled trial analysis supports Winrevair as PAH treatment

Winrevair (sotatercept) is generally safe and effective for people with pulmonary arterial hypertension (PAH) when given in addition to their standard of care treatment, a pooled analysis of two clinical trials shows. Along with other benefits, the clinical studies — the Phase 2 PULSAR trial (NCT03496207) and…

Celastrol has promise as preventive BPD-PH treatment in rat study

Celastrol, a herbal compound used in traditional Chinese medicine, may help prevent pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) by reducing inflammation and protecting lung tissue from damage, a study in rats and lab-grown cells suggests. While these preclinical findings are promising, the compound is still experimental and more…

CS1 improves right heart function in PAH: New trial data

Cereno Scientific‘s investigational oral therapy CS1 improves right heart function in people with pulmonary arterial hypertension (PAH), according to new data from a Phase 2a clinical trial. Three months of treatment also boosted quality of life, while symptoms associated with heart failure and the risk of clinical worsening…

Diaphragm neurostimulation eases PH during mechanical ventilation

Lungpacer Medical’s AeroNova diaphragm neurostimulation system significantly reduced pulmonary hypertension (PH) among critically ill patients with lung failure while they were on mechanical ventilation, according to data from the STIMULUS trial. The device, which electrically stimulates nerves to activate the diaphragm muscles in synchrony with mechanical ventilation, also…

GLS1 immune blockade reduces PAH indications in rat model

Blocking GLS1, an enzyme that drives pro-inflammatory immune macrophages, reduces the signs and symptoms of pulmonary arterial hypertension (PAH) in rats, a study reports. “This study offers a fresh outlook upon understanding the role of macrophages in PAH and provides experimental evidence in developing targeted therapeutic strategies,” the researchers…